<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961580</url>
  </required_header>
  <id_info>
    <org_study_id>fdpicu-23</org_study_id>
    <nct_id>NCT04961580</nct_id>
  </id_info>
  <brief_title>PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of Ceftazidime Avitbatan Sodium in Children With Severe Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ceftazidime avitbatan sodium is a broad-spectrum antibiotic with an antimicrobial spectrum&#xD;
      covering resistant gram-negative bacteria. Its use in pediatric intensive care for severe&#xD;
      infections is not unusual. Pathophysiological changes in severe sepsis can lead to&#xD;
      significant changes in pharmacokinetics and pharmacodynamics during continuous renal&#xD;
      replacement therapy.This research aims to study change of pharmacokinetic and pharmacodynamic&#xD;
      in severe infection children with extracorporeal life support, thus improve the treatment of&#xD;
      severe sepsis and sepsis shock.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an observational clinical study. Subjects were recruited from children with&#xD;
      severe infection receiving ceftazidime avitbatan sodium under routine clinical diagnosis and&#xD;
      treatment routine. There is no control, no double-blind randomized design, and the normal&#xD;
      treatment schedule of patients was not interfered with, and the disease risk of patients was&#xD;
      not increased.All subjects had received at least 5 doses of ceftazidime avitbatan Sodium&#xD;
      before enrollment.&#xD;
&#xD;
      Blood sampling time points of ceftazidime avitbatan sodium are listed as follow:&#xD;
&#xD;
      Before administration (0 min); 5,30 min,1 h,2 h,4 h and 8 h after administration, if blood&#xD;
      purification is received, one blood sample will be collected before and after the filter at&#xD;
      the same time point.&#xD;
&#xD;
      The concentration of ceftazidime avitbatan sodium in whole blood will be analyzed at Huashan&#xD;
      Hospital of Fudan University.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) Pharmacokinetic Parameter</measure>
    <time_frame>Day 1-5</time_frame>
    <description>Time to reach the maximum plasma concentration (Tmax) after administrations of a single dose and multiple doses of the study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Elimination Half-life (T1/2) Pharmacokinetic Parameter</measure>
    <time_frame>Day 1-5</time_frame>
    <description>Time required for half of the drug to be eliminated from the plasma after administration of a single dose of the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Pharmacokinetic Parameter</measure>
    <time_frame>Day 1-5</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to infinity after administration of a single dose of the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Pharmacokinetic Parameter</measure>
    <time_frame>Day1-5</time_frame>
    <description>Area under the curve from 0 to 24 hours after administrations of a single dose and multiple doses of the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration Pharmacokinetic Parameter</measure>
    <time_frame>Day1-5</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration after administrations of a single dose and multiple doses of the study drug</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sepsis</condition>
  <condition>Antibiotic Reaction</condition>
  <arm_group>
    <arm_group_label>Ceftazidime avitbatan sodiumt group</arm_group_label>
    <description>Children treated with ceftazidime avitbatan sodium in the pediatric intensive care unit will be enrolled in this group. Blood sample will be retained at various time intervals for pharmacokinetics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftazidime Avitbatan Sodium</intervention_name>
    <description>For 6-18 years children, 62.5 mg/kg/onceï¼Œq8h ; 3-6 months of age 50 mg/kg/ once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.</description>
    <arm_group_label>Ceftazidime avitbatan sodiumt group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children receiving cefatadine and averbactam sodium in pediatric intensive care unit&#xD;
        including but not limited to children with liver insufficiency, hypoproteinemia, ECMO&#xD;
        treatment, CRRT treatment or sepsis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children who are admitted in the pediatric intensive care unit receiving ceftazidime&#xD;
             avitbatan sodium&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No Informed Consent signed&#xD;
&#xD;
          -  Participate in other clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoping Lu, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yixue Wang, Doctor</last_name>
    <phone>8613524669352</phone>
    <email>yixuewang08@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children'S Hosptial of Fuan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftazidime</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

